

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/445,614	12/08/1999	Timothy Peter Bonnert	T1481	1165	
75	90 04/18/2006		EXAM	EXAMINER	
Patent Department			BRANNOCK, MICHAEL T		
Merck & Co Inc	C				
P.O. Box 2000		ART UNIT	PAPER NUMBER		
Rahway, NJ 07065-0907			1649		

DATE MAILED: 04/18/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	09/445,614	BONNERT, TIMOTHY PETER					
Office Action Summary	Examiner	Art Unit					
	Michael Brannock	1649					
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence ad	ldress				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period was provided by the office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	I. lely filed the mailing date of this c (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on 02 Fe	ebruary 2006.						
·	action is non-final.						
<i>,</i> —	· 						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4)⊠ Claim(s) <u>1-3 and 7-9</u> is/are pending in the appl	ication.						
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) ☐ Claim(s) <u>1-3 and 7</u> is/are allowed.							
6) ☐ Claim(s) <u>8 and 9</u> is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examine	r.						
10)⊠ The drawing(s) filed on <i>24 December 2003</i> is/are: a)⊠ accepted or b)□ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)⊠ All b)□ Some * c)□ None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s)							
) Notice of References Cited (PTO-892)	4) Interview Summary						
Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da 5) Notice of Informal P		∩_152\				
Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	6) Other:	atent Application (PTC	J-102)				

Application/Control Number: 09/445,614

Art Unit: 1649

DETAILED ACTION

Status of Application: Claims and Amendments

Applicant is notified that any outstanding objection or rejection that is not expressly maintained in this Office action has been withdrawn in view of Applicant's persuasive arguments of February 2, 2006.

Specifically the polypeptide of the instant SEQ ID NO: 2 is 100% identical to the polypeptide disclosed by US Patent Publication 2005/0158827 as SEQ ID NO: 5, which is encoded by a polynucleotide (SEQ ID NO: 4) that has an identical coding region with the instant SEQ ID NO: 1 and what appear to be minor differences in the 5'-noncoding regions, as set forth previously. The polypeptide of SEQ ID NO: 5 and the encoding polynucleotide of SEQ ID NO: 4 of US Patent Publication 2005/0158827 appear to be fully supported by prior application 09/258633 filed 2/26/1999, however there does not appear to be support for the full length SEQ ID NO: 5 polypeptide in either prior application 60/114078 or 60/108322. Additionally, Applicant correctly points out that the Foreign priority claim of the instant application has perfected and acknowledged previously.

New Rejection:

35 U.S.C. §101 states:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 8 and 9 are rejected under 35 USC §101 because the claimed invention is directed to non-statutory subject matter. The specification states that the invention relates to host cells and

Art Unit: 1649

organisms transformed with expression vectors containing vr-1. Thus the cell could be present or intended to be present in a human being, said cell becoming integrated into the human being and therefore being an inseparable part of the human itself. The scope of the claim, therefore, encompasses a human being, which is non-statutory subject matter. As such, the recitation of the limitation "non-human" or "isolated host cell" would be remedial. See 1077 O.G. 24, April 21, 1987.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Brannock, Ph.D., whose telephone number is (571) 272-0869. The examiner can normally be reached on Mondays through Fridays from 10:00 a.m. to 4:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, Ph.D., can be reached at (571) 272-0867. Official papers filed by fax should be directed to 571-273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

MB

ELIZABETH KEMMERER **PRIMARY EXAMINER**

Elyaber C. Kemmen

April 16, 2004